The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer.

SEQUEIRA, GONZALO; VANZULLI, SILVIA; ROJAS, PAOLA; LAMB, CAROLINE; COLOMBO, LUCAS; MAY, MARÍA; MOLINOLO, ALFREDO; LANARI, CLAUDIA

Oncotarget

Impact Journals, LLC

Lugar: Depew; Año: 2014 vol. 5 p. 3246 - 3260

There is clinical and experimental evidence suggesting that antiprogestins might be used for the treatment of selected breast cancer patients. Our aim was to evaluate the effect of albumin-bound paclitaxel (Nab-paclitaxel) and pegylated doxorubicin liposomes (PEG-LD) in combination with mifepristone (MFP) in experimental breast cancer models expressing different ratios of progesterone receptor (PR) isoforms A and B. We used two antiprogestin-responsive (PRA>PRB) and two resistant (PRA